Acutus Medical Analyst Ratings
Acutus Medical Analyst Ratings
While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $1.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $1.45, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | 3.45% | Goldman Sachs | $1 → $1.5 | Maintains | Neutral |
| 06/24/2022 | 3.45% | BTIG | $2 → $1.5 | Maintains | Buy |
| 04/27/2022 | 37.93% | BTIG | → $2 | Upgrades | Neutral → Buy |
| 04/14/2022 | -31.03% | Goldman Sachs | $5 → $1 | Maintains | Neutral |
| 01/20/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 01/14/2022 | 106.9% | Canaccord Genuity | $10 → $3 | Downgrades | Buy → Hold |
| 11/12/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/12/2021 | 589.66% | Canaccord Genuity | $18 → $10 | Maintains | Buy |
| 10/22/2021 | 589.66% | Goldman Sachs | → $10 | Initiates Coverage On | → Neutral |
| 07/15/2021 | 1141.38% | Canaccord Genuity | $11 → $18 | Upgrades | Hold → Buy |
| 03/19/2021 | 1003.45% | Canaccord Genuity | $30 → $16 | Maintains | Hold |
| 03/19/2021 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/19/2021 | 1210.34% | JP Morgan | → $19 | Downgrades | Overweight → Neutral |
| 01/14/2021 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 08/31/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 08/31/2020 | 1968.97% | Canaccord Genuity | → $30 | Initiates Coverage On | → Hold |
| 08/31/2020 | 2520.69% | B of A Securities | → $38 | Initiates Coverage On | → Buy |
| 08/31/2020 | 2589.66% | JP Morgan | → $39 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析师事务所 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/16/2022 | 3.45% | 高盛 | $1 → 1.5 美元 | 维护 | 中立 |
| 2022 年 6 月 24 日 | 3.45% | BTIG | $2 → 1.5 美元 | 维护 | 购买 |
| 04/27/2022 | 37.93% | BTIG | → 2 美元 | 升级 | 中性 → 买入 |
| 2022 年 4 月 14 日 | -31.03% | 高盛 | 5 美元 → 1 美元 | 维护 | 中立 |
| 01/20/2022 | — | BTIG | 降级 | 买入 → 中性 | |
| 2022 年 1 月 14 日 | 106.9% | Canaccord Genu | 10 美元 → 3 美元 | 降级 | 买入 → 持有 |
| 11/12/2021 | — | 摩根大通 | 降级 | 中性 → 体重不足 | |
| 11/12/2021 | 589.66% | Canaccord Genu | 18 美元 → 10 美元 | 维护 | 购买 |
| 2021 年 10 月 22 日 | 589.66% | 高盛 | → 10 美元 | 启动覆盖范围开启 | → 中立 |
| 2021 年 7 月 15 日 | 1141.38% | Canaccord Genu | 11 美元 → 18 美元 | 升级 | 持有 → 买入 |
| 03/19/2021 | 1003.45% | Canaccord Genu | 30 美元 → 16 美元 | 维护 | 保持 |
| 03/19/2021 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 03/19/2021 | 1210.34% | 摩根大通 | → 19 美元 | 降级 | 超重 → 中性 |
| 2021 年 1 月 14 日 | — | B of A 类证券 | 降级 | 买入 → 中性 | |
| 08/31/2020 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 08/31/2020 | 1968.97% | Canaccord Genu | → 30 美元 | 启动覆盖范围开启 | → 按住 |
| 08/31/2020 | 2520.69% | B of A 类证券 | → 38 美元 | 启动覆盖范围开启 | → 购买 |
| 08/31/2020 | 2589.66% | 摩根大通 | → 39 美元 | 启动覆盖范围开启 | → 超重 |
Acutus Medical Questions & Answers
Acutus 医学问题与解答
The latest price target for Acutus Medical (NASDAQ: AFIB) was reported by Goldman Sachs on August 16, 2022. The analyst firm set a price target for $1.50 expecting AFIB to rise to within 12 months (a possible 3.45% upside). 9 analyst firms have reported ratings in the last year.
高盛于2022年8月16日公布了Acutus Medical（纳斯达克股票代码：AFIB）的最新目标股价。该分析公司将目标股价设定为1.50美元，预计AFIB将在12个月内上涨至1.50美元（可能上涨3.45％）。去年有9家分析公司公布了评级。
The latest analyst rating for Acutus Medical (NASDAQ: AFIB) was provided by Goldman Sachs, and Acutus Medical maintained their neutral rating.
Acutus Medical（纳斯达克股票代码：AFIB）的最新分析师评级由高盛提供，Acutus Medical维持中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acutus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acutus Medical was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Acutus Medical的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Acutus Medical的最后一次评级是在2022年8月16日提交的，因此您应该预计下一个评级将在2023年8月16日左右公布。
While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $1.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $1.45, which is within the analyst's predicted range.
尽管评级是主观的，并将发生变化，但最新的Acutus Medical（AFIB）评级维持不变，目标股价为1.00美元至1.50美元。Acutus Medical（AFIB）目前的交易价格为1.45美元，在分析师的预测区间内。
